Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States each year and for which there are no FDA - approved treatments. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to mitigate the effects of the elevated and abnormal release patterns of cortisol seen in PMD. In August 2006 we announced negative top line results of one of our three Phase 3 studies. We expect to report the results the second study in September and the third in late 2006 or early 2007. Our program has been granted "fast track" status by the FDA. We have also initiated a proof-of-concept study evaluating the ability of CORLUX to mitigate weight gain associated with the use of olanzapine.

Contact Details: 149 Commonwealth Drive Menlo Park California 94025 United States of America Tel: (650) 327-3270 Fax: (650) 327-3218 Email: info@corcept.com WWW: www.corcept.com/

Loading...

Recent Publications by Corcept Therapeutics:
Glucocorticoid receptor antagonists. This review covers recent progress in the discovery of selective...	25th July, 2008	Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA.	Curr Top Med Chem. 2008;8(9):813-38.
1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity. Addition of the 4-fluorophenylpyrazole group to the previously described...	13th May, 2008	Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA.	Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. Epub 2008 Jan 11. DOI Direct Link
2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists. The 2-azadecalin ring system was evaluated as a scaffold for the...	13th December, 2007	Corcept Therapeutics, 149 Commonwealth Avenue, Menlo Park, CA 94025, USA.	Bioorg Med Chem Lett. 2007 Oct 15;17(20):5704-8. Epub 2007 Aug 19. DOI Direct Link
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. BACKGROUND: Abnormalities in the hypothalamic pituitary adrenal axis have...	24th January, 2007	Corcept Therapeutics,	Biol Psychiatry. 2006 Dec 15;60(12):1343-9. Epub 2006 Aug 4. DOI Direct Link
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Atypical antipsychotics, such as olanzapine, have been associated with...	26th September, 2006	Corcept Therapeutics, Menlo Park, CA 94205, USA.	Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19. DOI Direct Link
→View more Corcept Therapeutics research publications.

BioNews Results for Corcept Therapeutics:
Corcept Therapeutics continues collaboration with Eli Lilly	PharmaBiz:  Sep 5 2008 10:14AM Matching: corcept therapeutics
Corcept Therapeutics: Corcept Therapeutics Continues Collaboration With Eli Lilly and Company	Market Wire:  Sep 3 2008 1:25PM Matching: corcept therapeutics
Corcept Therapeutics Continues Collaboration With Eli Lilly and Company	Market Wire:  Sep 3 2008 1:16PM Matching: corcept therapeutics
Continues Collaboration With Eli Lilly and Company	Therapeutics Daily:  Sep 3 2008 3:27PM Matching: corcept therapeutics
Corcept Therapeutics Continues Collaboration With Eli Lilly and Company	Macro World Investor:  Sep 3 2008 1:34PM Matching: corcept therapeutics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Corcept Therapeutics news.

Corcept Therapeutics Patents:
US Patent No.	Title
7402578	Methods for inhibiting cognitive deterioration in adults with down's syndrome
7361646	Methods for treating gastroesophageal reflux disease
7326697	Methods for increasing the therapeutic response to electroconvulsive therapy
7163934	Methods for treating delirium glucocorticoid receptor-specific antagonists
6964953	Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
→View more Corcept Therapeutics patents.

Corcept Therapeutics (CORT) Financial information Links from Barchart
CORT Quote from from Barchart.com
CORT Chart from from Barchart.com
CORT Profile from from Barchart.com
CORT Opinion from from Barchart.com
→View more Corcept Therapeutics finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 188 times since April 2007, the link to the organisation's website has been followed 31 times

Recent Search Terms used to find this page: Corcept Therapeutics 149 Commonwealth Avenue Menlo Park CA 94025 | corcept therapeutic | corcept therapetic ca | @corcept.com .AND. development | corcept.com | t | 6 680 310 patent | corcept neuroinvestment | Corcept Therapeutics | neuroinvestment corcept | .

Search for more companies in Menlo Park

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Corcept Therapeutics